{"id":"NCT05590793","sponsor":"Ipsen","briefTitle":"Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate","officialTitle":"A Multicentre, Open-label, Single-arm Study to Investigate the Efficacy and Safety of Triptorelin Pamoate 22.5 mg 6-month Formulation in Chinese Patients With Locally Advanced or Metastatic Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-11-17","primaryCompletion":"2024-08-20","completion":"2024-08-20","firstPosted":"2022-10-21","resultsPosted":"2025-09-09","lastUpdate":"2025-09-09"},"enrollment":195,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Prostate Cancer","Metastatic Prostate Cancer","Locally Advanced Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Triptorelin pamoate (embonate) salt","otherNames":["Dipherelin"]}],"arms":[{"label":"Triptorelin pamoate 22.5 mg 6-month formulation","type":"EXPERIMENTAL"}],"summary":"The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Castrate Levels of Serum Testosterone on Day 29","timeFrame":"Day 29","effectByArm":[{"arm":"Triptorelin Pamoate","deltaMin":99.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":36,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":195},"commonTop":["Upper respiratory tract infection","Cough","Anaemia","Nasopharyngitis","Hyperhidrosis"]}}